Peer-Reviewed Glioma Surgery Study With Cellectar Biosciences Fluorescence Cancer-Targeting Agents Chosen for the Cover of Ne...
22 Januar 2015 - 2:30PM
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage
biopharmaceutical company developing innovative agents for the
detection and treatment of cancer, announced publication of the
first peer-reviewed proof-of-principle study of a new class of
fluorescent alkylphosphocholine analogs for fluorescence-guided
glioma surgery in Neurosurgery, official journal of the Congress of
Neurological Surgeons – the largest neurosurgical society in the
world. This study is featured on the cover of the February 2015
issue, and demonstrates that the fluorescent cancer-selective
CLR1501 and CLR1502 agents successfully provide visualization of
glioma cancer cells with high fidelity, and suggest their practical
and promising potential to optimize tumor surgery.
Cancer surgeons are challenged to better discriminate cancer
cells from normal tissue, and are exploring the use of fluorescence
agents to optimize tumor visualization and maximize safe surgical
resection. Using its highly selective cancer-targeting phospholipid
ether (PLE) technology, Cellectar has developed CLR1501 and CLR1502
as novel tumor-selective fluorescent agents to illuminate cancer
cells, in vitro and in vivo respectively, thereby distinguishing
cancer from normal tissue during diagnostic, staging, debulking and
curative cancer surgeries.
The study's objectives were to confirm CLR1501 and CLR1502
cancer-cell selectivity in glioblastoma models, and to quantify
their fluorescent signals that distinguish tumor from normal brain
in comparison to 5-ALA, an agent commercially available in the
European Union for image-guided surgery but not approved for
routine use in the United States. This study showed that the
CLR1501 tumor-specific fluorescence signal is similar to 5-ALA, and
that CLR1502 has a superior tumor-to-brain fluorescence ratio.
"There is compelling evidence from a growing number of
peer-reviewed studies that demonstrate the ability of Cellectar PLE
agents to selectively target cancer cells," said senior author,
John S. Kuo, MD, PhD, Associate Professor of Neurological Surgery,
Director of the Comprehensive Brain Tumor Program and Chair of the
Carbone Cancer Center CNS Tumors Group at the University of
Wisconsin-Madison. "Using fluorescent Cellectar PLE agents for
real-time, intraoperative discrimination of cancer from adjacent
normal tissue promises to optimize tumor removal and preserve
critical normal tissue. Since Cellectar PLE technology successfully
targets many different cancers, CLR1502 has great potential to
significantly advance tumor fluorescence-guided surgery and improve
clinical outcomes for many surgically managed cancers."
Cellectar plans to initiate a Phase I proof-of-principle
clinical trial of CLR1502 in patients undergoing breast cancer
surgery later in 2015.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing agents to detect, treat and
monitor a broad spectrum of cancers. Using a novel phospholipid
ether (PLE) analog platform technology as a targeted delivery and
retention vehicle, Cellectar's compounds are designed to be
selectively taken up and retained in cancer cells including cancer
stem cells. With the ability to attach both imaging and therapeutic
agents to its proprietary delivery platform, Cellectar has
developed a portfolio of product candidates engineered to leverage
the unique characteristics of cancer cells to "find, treat and
follow" malignancies in a highly selective way. I-124-CLR1404 is a
small-molecule, broad-spectrum, cancer-targeted PET imaging agent
currently being evaluated in a Phase II glioblastoma imaging trial.
Additionally, multiple investigator-sponsored Phase I/II clinical
trials are ongoing across 11 solid tumor indications. I-131-CLR1404
is a small-molecule, broad-spectrum, cancer-targeted molecular
radiotherapeutic that delivers cytotoxic radiation directly and
selectively to cancer cells including cancer stem cells. A Phase Ib
dose-escalation trial of I-131-CLR1404 in patients with advanced
solid tumors was completed in the first quarter of 2014 and results
presented at the American Society of Clinical Oncology (ASCO) 2014
Annual Meeting. CLR1502 is a preclinical, cancer-targeted,
non-radioactive optical imaging agent for intraoperative tumor
margin illumination and non-invasive tumor imaging. For additional
information please visit www.cellectar.com
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form 10-K
for the year ended December 31, 2013. These forward-looking
statements are made only as of the date hereof, and we disclaim any
obligation to update any such forward-looking statements.
CONTACT: INVESTOR CONTACT
Kate McNeil, Vice President of IR, PR & Corporate Communications
Cellectar Biosciences, Inc.
Phone: (347) 204-4226
Email: kmcneil@cellectar.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2024 bis Aug 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Aug 2023 bis Aug 2024